Search for: "Novartis Pharmaceuticals Corporation" Results 61 - 80 of 145
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Nov 2011, 5:00 am by Bexis
Novartis Pharmaceuticals Corp., 2011 WL 5835414, slip op. [read post]
30 Dec 2012, 3:30 am by Gene Quinn & Angel Krippner
On October 31, 2012, Acacia Research Corporation (Nasdaq:ACTG) announced that its subsidiaries... [read post]
2 Mar 2010, 6:28 am by John J. Cord
Up until now, online social networking has been treated mostly as a plaything for some pharmaceutical manufacturers. [read post]
26 Mar 2011, 10:17 am
It is another in a spate of gender discrimination lawsuits filed recently against large corporations: last Monday a class action lawsuit was filed against Bayer HealthCare Pharmaceuticals and its parent, Bayer Corp., both U.S. units of Bayer AG, alleging the company has engaged in various discriminatory behaviors against its female employees. (1) The lawsuit, filed in U.S. [read post]
25 Aug 2010, 7:37 am by Levin & Perconti
The drug is manufactured by Finnish drugmaker Orion Corporation and is marked by Swiss-based Novartis Pharmaceuticals. [read post]
3 May 2013, 6:33 pm by Swaraj Paul Barooah
One can hope that (while certainly corporations are people too), this '... for the people' government is trying to sort out their own (non-corporation) people's medical problems with the same vigour, for, at last check, they were still having plenty of issues with medical bills. [read post]
30 Aug 2009, 10:00 pm
Bivins (a citizen of Texas) sued Novartis Pharmaceuticals (a Delaware corporation with its principal place of business in New Jersey), Novartis Pharma GmbH (a German corporation), and Novartis AG (a Swiss corporation) in New Jersey state court. [read post]
15 Oct 2008, 8:38 am
"In effect the Bush administration made the safety of Americans secondary to corporate profits. [read post]
27 Sep 2010, 12:59 am by FDABlog HPM
Karst –    Just two days after Novartis Pharmaceuticals Corporation (“Novartis”) filed a Complaint in the U.S. [read post]
18 Mar 2014, 9:13 am by Saurabh Anand
  In addition, in July 2010, FDA issued an untitled letter to Novartis Pharmaceuticals Corporation relating to the “Facebook Share” widget on its Tasigna® product website. [read post]
6 Aug 2015, 2:08 pm by Tom Lamb
As regards the resulting August 2015 revision to the Gilenya Prescribing Information (also known as "package insert" and "drug label"), the FDA SUPPLEMENT APPROVAL letter (8/4/15) to Novartis Pharmaceuticals Corporation sets the stage: This supplemental application provides for addition of a new subsection to the Warnings and Precautions section of the prescribing information; the new subsection [5.3] describes the cases of progressive multifocal… [read post]
2 Nov 2015, 2:05 pm by Michael Rosenblat
  (See, Blog post DOJ to Focus on Individual Accountability for Corporate Fraud.) [read post]
29 Mar 2012, 10:00 pm by Stephanie Figueroa
Prometheus. 3) Intellectual Property Watch: Novartis India Challenge Postponed To July – This post shares how the Indian Supreme Court today postponed hearing the high-profile case involving Swiss pharmaceutical producer Novartis’ challenge of India’s patent law until July. 4) Patents Post-Grant: AIA Changes to Greatly Increase Stays of District Court Actions – This post discusses the estoppel provisions of Post Grant Review and Inter Partes Review and how they… [read post]
15 Feb 2011, 4:06 am by Andrew Frisch
Unlike conventional retail sales, the patient is not at liberty to choose personally which prescription pharmaceutical he desires. [read post]
5 May 2010, 5:14 pm by FDABlog HPM
Martin – FDA just released the Warning Letter it issued to Novartis Pharmaceuticals Corporation (“Novartis”) in April regarding two purportedly unbranded websites, www.gistalliance.com and www.cmlalliance.com (the “alliance websites”), which included disease-state information and clinical data about gastrointestinal stromal tumors (“GIST”) and chronic myeloid leukemia (“CML”).  [read post]
3 Mar 2013, 9:37 am by FDABlog HPM
  Late last week, Sun Pharma Global FZE, Caraco Pharmaceutical Laboratories, Ltd., and Sun Pharmaceuticals Industries, Ltd. [read post]
12 Mar 2013, 6:20 am by Bexis
Novartis Pharmaceutical Corp., 2012 WL 5398219 (Mag. [read post]
18 Apr 2011, 5:51 pm by FDABlog HPM
Prior to joining HP&M, Linda served in several pharmaceutical industry positions, including as Senior Director, Global Regulatory Policy and Intelligence, Janssen Pharmaceutical Companies of Johnson & Johnson, Executive Director, FDA Liaison, Drug Regulatory Affairs, Novartis Pharmaceuticals Corporation, and Director, Global Regulatory Affairs, Legislative Policy and Regulatory Liaison, Pharmacia Corporation.  [read post]